Literature DB >> 26517304

Dysregulation of Antiviral Function of CD8(+) T Cells in the Chronic Obstructive Pulmonary Disease Lung. Role of the PD-1-PD-L1 Axis.

Richard T McKendry1, C Mirella Spalluto1, Hannah Burke1, Ben Nicholas1, Doriana Cellura1, Aymen Al-Shamkhani1, Karl J Staples1, Tom M A Wilkinson1,2.   

Abstract

RATIONALE: Patients with chronic obstructive pulmonary disease (COPD) are susceptible to respiratory viral infections that cause exacerbations. The mechanisms underlying this susceptibility are not understood. Effectors of the adaptive immune response-CD8(+) T cells that clear viral infections-are present in increased numbers in the lungs of patients with COPD, but they fail to protect against infection and may contribute to the immunopathology of the disease.
OBJECTIVES: CD8(+) function and signaling through the programmed cell death protein (PD)-1 exhaustion pathway were investigated as a potential key mechanism of viral exacerbation of the COPD lung.
METHODS: Tissue from control subjects and patients with COPD undergoing lung resection was infected with live influenza virus ex vivo. Viral infection and expression of lung cell markers were analyzed using flow cytometry.
MEASUREMENTS AND MAIN RESULTS: The proportion of lung CD8(+) T cells expressing PD-1 was greater in COPD (mean, 16.2%) than in controls (4.4%, P = 0.029). Only epithelial cells and macrophages were infected with influenza, and there was no difference in the proportion of infected cells between controls and COPD. Infection up-regulated T-cell PD-1 expression in control and COPD samples. Concurrently, influenza significantly up-regulated the marker of cytotoxic degranulation (CD107a) on CD8(+) T cells (P = 0.03) from control subjects but not on those from patients with COPD. Virus-induced expression of the ligand PD-L1 was decreased on COPD macrophages (P = 0.04) with a corresponding increase in IFN-γ release from infected COPD explants compared with controls (P = 0.04).
CONCLUSIONS: This study has established a signal of cytotoxic immune dysfunction and aberrant immune regulation in the COPD lung that may explain both the susceptibility to viral infection and the excessive inflammation associated with exacerbations.

Entities:  

Keywords:  PD-1; T cell; chronic obstructive pulmonary disease; macrophage; viral infection

Mesh:

Substances:

Year:  2016        PMID: 26517304      PMCID: PMC4824936          DOI: 10.1164/rccm.201504-0782OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  38 in total

Review 1.  Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy.

Authors:  R H Schwartz
Journal:  Cell       Date:  1992-12-24       Impact factor: 41.582

2.  Cutting edge: MHC class II-restricted killing in vivo during viral infection.

Authors:  Evan R Jellison; Sung-Kwon Kim; Raymond M Welsh
Journal:  J Immunol       Date:  2005-01-15       Impact factor: 5.422

Review 3.  Epidemiology and costs of chronic obstructive pulmonary disease.

Authors:  K R Chapman; D M Mannino; J B Soriano; P A Vermeire; A S Buist; M J Thun; C Connell; A Jemal; T A Lee; M Miravitlles; S Aldington; R Beasley
Journal:  Eur Respir J       Date:  2006-01       Impact factor: 16.671

4.  CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease.

Authors:  M Saetta; A Di Stefano; G Turato; F M Facchini; L Corbino; C E Mapp; P Maestrelli; A Ciaccia; L M Fabbri
Journal:  Am J Respir Crit Care Med       Date:  1998-03       Impact factor: 21.405

5.  CD8+ T cells clear influenza virus by perforin or Fas-dependent processes.

Authors:  D J Topham; R A Tripp; P C Doherty
Journal:  J Immunol       Date:  1997-12-01       Impact factor: 5.422

6.  Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus.

Authors:  K L Yap; G L Ada; I F McKenzie
Journal:  Nature       Date:  1978-05-18       Impact factor: 49.962

7.  Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.

Authors:  Y Agata; A Kawasaki; H Nishimura; Y Ishida; T Tsubata; H Yagita; T Honjo
Journal:  Int Immunol       Date:  1996-05       Impact factor: 4.823

8.  Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1.

Authors:  T C O'Shaughnessy; T W Ansari; N C Barnes; P K Jeffery
Journal:  Am J Respir Crit Care Med       Date:  1997-03       Impact factor: 21.405

9.  New strains of bacteria and exacerbations of chronic obstructive pulmonary disease.

Authors:  Sanjay Sethi; Nancy Evans; Brydon J B Grant; Timothy F Murphy
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

10.  Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus.

Authors:  Peter A B Wark; Sebastian L Johnston; Fabio Bucchieri; Robert Powell; Sarah Puddicombe; Vasile Laza-Stanca; Stephen T Holgate; Donna E Davies
Journal:  J Exp Med       Date:  2005-03-21       Impact factor: 14.307

View more
  40 in total

Review 1.  Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities.

Authors:  Mathew Suji Eapen; Philip M Hansbro; Anna-Karin Larsson-Callerfelt; Mohit K Jolly; Stephen Myers; Pawan Sharma; Bernadette Jones; Md Atiqur Rahman; James Markos; Collin Chia; Josie Larby; Greg Haug; Ashutosh Hardikar; Heinrich C Weber; George Mabeza; Vinicius Cavalheri; Yet H Khor; Christine F McDonald; Sukhwinder Singh Sohal
Journal:  Drugs       Date:  2018-11       Impact factor: 9.546

2.  Immune phenotypes in lung cancer patients with COPD: potential implications for immunotherapy.

Authors:  Roberto Chalela; Joaquim Gea; Esther Barreiro
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

3.  At the Checkpoint: Lung CD8(+) T Cells, Respiratory Viruses, and Chronic Obstructive Pulmonary Disease.

Authors:  Jeffrey L Curtis
Journal:  Am J Respir Crit Care Med       Date:  2016-03-15       Impact factor: 21.405

Review 4.  The respiratory microbiome: an underappreciated player in the human response to inhaled pollutants?

Authors:  Sara D Adar; Gary B Huffnagle; Jeffrey L Curtis
Journal:  Ann Epidemiol       Date:  2016-04-07       Impact factor: 3.797

5.  Emphysema assessment for personalized immunotherapy response prediction in lung cancer patients.

Authors:  Dimitra Kerdidani; Sophia Magkouta; Maria Tsoumakidou
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

6.  Effect of an Exercise Program on Lymphocyte Proliferative Responses of COPD Patients.

Authors:  Juliana Ruiz Fernandes; Cibele Cristine Berto Marques da Silva; Aline Grandi da Silva; Regina Maria de Carvalho Pinto; Alberto José da Silva Duarte; Celso Ricardo Carvalho; Gil Benard
Journal:  Lung       Date:  2018-03-10       Impact factor: 2.584

Review 7.  Chronic obstructive pulmonary disease (COPD) and lung cancer: common pathways for pathogenesis.

Authors:  Brielle A Parris; Hannah E O'Farrell; Kwun M Fong; Ian A Yang
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

8.  Chronic Obstructive Pulmonary Disease Alters Immune Cell Composition and Immune Checkpoint Inhibitor Efficacy in Non-Small Cell Lung Cancer.

Authors:  Nicholas M Mark; Julia Kargl; Stephanie E Busch; Grace H Y Yang; Heather E Metz; Huajia Zhang; Jesse J Hubbard; Sudhakar N J Pipavath; David K Madtes; A McGarry Houghton
Journal:  Am J Respir Crit Care Med       Date:  2018-02-01       Impact factor: 21.405

Review 9.  Influenza vaccination for patients with chronic obstructive pulmonary disease: understanding immunogenicity, efficacy and effectiveness.

Authors:  Farzaneh Sanei; Tom Wilkinson
Journal:  Ther Adv Respir Dis       Date:  2016-05-18       Impact factor: 4.031

10.  Cytometry TOF identifies alveolar macrophage subtypes in acute respiratory distress syndrome.

Authors:  Eric D Morrell; Alice Wiedeman; S Alice Long; Sina A Gharib; T Eoin West; Shawn J Skerrett; Mark M Wurfel; Carmen Mikacenic
Journal:  JCI Insight       Date:  2018-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.